These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25487083)

  • 1. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
    Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
    Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy.
    Mennini FS; Panatto D; Marcellusi A; Cristoforoni P; De Vincenzo R; Di Capua E; Ferrandina G; Petrillo M; Sasso T; Ricci C; Trivellizzi N; Capone A; Scambia G; Gasparini R
    Clin Ther; 2011 Aug; 33(8):1084-1095.e4. PubMed ID: 21788076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A; Ovcinnikova O; Palmer C; Engelbrecht K; Reuschenbach M; Daniels V
    JAMA Netw Open; 2024 Oct; 7(10):e2437703. PubMed ID: 39365579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
    Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
    Ezat WP; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HPV vaccination: health gains in the Italian female population.
    Marcellusi A
    Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E; Reuschenbach M; Viering T; Luzak A; Greiner W; Hampl M; Jacob C
    Arch Gynecol Obstet; 2024 Nov; 310(5):2639-2646. PubMed ID: 39230793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
    Isaranuwatchai W; Graham DM; Siu LL; Hoch JS
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):763-5. PubMed ID: 25095728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia.
    Sehnal B; Dusek L; Cibula D; Zima T; Halaska M; Driak D; Slama J
    J Clin Virol; 2014 Jan; 59(1):18-23. PubMed ID: 24315797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.